179 Immunotherapy trials lack a biomarker for inclusion: implications for drug development
Razelle Kurzrock,
Shumei Kato,
Jacob Adashek,
Alexey Goloubev
Affiliations
Razelle Kurzrock
Aff4 0000 0001 2107 4242grid.266100.3Center for Personalized Cancer Therapy and Clinical Trials Office, Division of Hematology and Oncology, Clinical Science, Department of MedicineUniversity of California San Diego Moores Cancer Center 3855 Health Sciences Drive 92093 La Jolla CA USA
Shumei Kato
Center for Personalized Cancer Therapy, UC San Diego Moores Cancer Center, La Jolla, California, USA
Jacob Adashek
1University of South Florida, Moffitt Cancer Center, Tampa, FL, USA
